Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 10% year on year to $862.7 million. The company’s full-year revenue guidance of $3.2 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.26 per share was 9.5% above analysts’ consensus estimates.

Is now the time to buy AMRX? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Amneal’s third quarter was characterized by strong revenue growth driven by new product launches and expansion in biosimilars and complex generics. Management attributed the performance to the integration of Kashiv’s biosimilars platform, robust specialty drug uptake, and growth in women’s health products. CEO Chirag Patel highlighted, “Our third quarter performance reflects that progress...with revenue of $863 million, up 10%.” Favorable product mix, operational execution, and contributions from recent approvals, such as lanreotide, supported margin improvement.

Looking forward, Amneal’s updated guidance is underpinned by expanding capacity in biosimilars, ongoing specialty drug growth, and an evolving complex generics pipeline. Management expects additional approvals and market entries, including XOLAIR biosimilar and further GLP-1 progress through the Pfizer partnership, to drive future gains. CFO Tasos Konidaris noted that increasing gross margins are expected over the long term as “biosimilars in general have a higher gross margin than the rest of our business.” Management also emphasized that investments in manufacturing and automation will expand long-term profitability and sustain new product launches across multiple therapeutic areas.

Key insights from management’s remarks

Management cited portfolio breadth, pipeline progress, and operational upgrades as core drivers of the quarter’s performance and improved outlook.

• Biosimilars platform integration: The Kashiv acquisition brought end-to-end biosimilar capabilities, allowing Amneal to manage R&D, manufacturing, and commercialization internally. Management expects this to accelerate launches and capture better economics, particularly as large biologics lose exclusivity in coming years.

• Complex generics momentum: New approvals and launches in categories like women’s health transdermal patches and injectables contributed meaningfully to growth. The company’s focus on complex, higher-value generics—such as lanreotide and iohexol—helped differentiate its portfolio and improve profitability.

• Specialty business expansion: CREXONT (Parkinson’s) and BREKIYA (migraine/cluster headache) continued to gain share, aided by positive patient outcomes and physician adoption. Management reported strong prescription growth and stated that not many payers have blocked BREKIYA yet, but noted that they will continue to monitor access as uptake progresses. Additional specialty pipeline assets are in development.

• Manufacturing and operational investments: Facility digitization, automation, and capacity expansion supported efficiency gains and readiness for future launches, including new GLP-1, sterile injectables, and biosimilar products. These upgrades are designed to ensure reliable supply and scalable growth.

• AvKARE and government channels: Although AvKARE revenue declined due to a non-recurring product launch last year, its adjusted EBITDA improved. Management is prioritizing profitability and sees AvKARE as a channel for future biosimilar and specialty product flow into government and institutional markets.

Drivers of future performance

Amneal’s forward outlook is shaped by its biosimilars pipeline, specialty growth, and ongoing manufacturing investments, with margin improvement expected from product mix shifts.

• Biosimilars and complex generics pipeline: Management expects the majority of future revenue growth to come from biosimilars, supported by the Kashiv integration. Early-to-market launches, like XOLAIR and denosumab biosimilars, are planned, with new approvals targeted for both U.S. and European markets. Complex generics, including inhalation and sterile injectables, are positioned as additional growth drivers.

• Specialty product scaling: CREXONT and BREKIYA are projected to sustain high prescription growth, with further clinical data and expanded capacity supporting broader physician adoption. Management is also developing new specialty assets, aiming to build a larger portfolio of differentiated branded products.

• Operational efficiency and capacity expansion: Ongoing investments in automation, digitization, and manufacturing expansion are expected to support higher margins and reliable product supply. These initiatives should enable Amneal to capitalize on growing demand across biosimilars, generics, and specialty segments, while supporting international market entry.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will be monitoring (1) progress on new biosimilar approvals and U.S. and European launches, especially XOLAIR and denosumab, (2) continued expansion and uptake in specialty products like CREXONT and BREKIYA, and (3) the impact of manufacturing investments on both operational efficiency and ability to support new product rollouts. Execution on product pipeline milestones and international market entry will also be key to tracking sustained growth.

Amneal currently trades at $20.08, down from $20.44 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High quality stocks for all market conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.